The Cognitive Stack: Semax + Selank

Research disclaimer: These compounds are sold for research purposes only and are not intended for human consumption.

Evidence Tier for This Combination

Moderate — individual compound evidence is stronger than combination evidence.

Both Semax and Selank have been studied clinically in Russia and registered as medicines. Human data exists for each compound separately. There are no published studies specifically examining the combination. The rationale for stacking them is mechanistic — their pathways are complementary and non-overlapping — not derived from controlled trials of the pair.

Why These Two Work Together

Most cognitive enhancers create a trade-off: stimulants raise focus but also anxiety; anxiolytics reduce anxiety but blunt alertness. Semax and Selank avoid this because they work through different systems entirely.

Semax is a synthetic analog of ACTH(4-7) with a Pro-Gly-Pro extension that dramatically extends its half-life. Its primary effects are BDNF and NGF upregulation — it drives neurotrophin synthesis, which supports synaptic plasticity, working memory, and attention. It also acts on the dopaminergic system, which contributes to motivated focus. In clinical use in Russia it is prescribed for stroke recovery, cognitive decline, and ADHD. The subjective effect is increased drive and mental clarity.

Selank is a synthetic analog of tuftsin with a stabilising tripeptide extension. Its anxiolytic mechanism runs through GABA modulation and serotonin regulation — specifically it inhibits enkephalin degradation, which prolongs the natural calming signal in the brain. It has been studied in Russia for generalised anxiety disorder and produces anxiolysis without sedation. It does not impair reaction time or working memory at research doses.

The combination addresses a real problem: many users of Semax report that the increased alertness and drive can tip into restlessness or a mild edge, particularly at higher doses. Selank smooths this without reducing the cognitive enhancement. The result — when it works — is focused calm rather than wired focus.

Neither compound depends on the other’s mechanism. Semax does not require a GABAergic context to work; Selank does not require neurotrophin activity to be anxiolytic. They are parallel rather than synergistic in a strict pharmacological sense, but the clinical outcome of combining them is more useful than either alone for most research purposes.

Timing Protocol

Both compounds are administered intranasally, which simplifies the protocol. No separate injection sites, no different reconstitution requirements.

Morning protocol (standard):

Both can be administered simultaneously or within a few minutes of each other. Alternating nostrils is standard practice — one spray per nostril.

Split dosing (higher demand days):

Some researchers use a second dose of Semax in early afternoon (no later than early afternoon to avoid sleep disruption). Selank can be re-dosed if anxiety returns, as its half-life is very short (plasma clearance within a few minutes, though CNS effects persist longer).

Cycle length: 14–21 days on, 7–14 days off is the most common pattern based on the clinical literature. Continuous use data does not exist.

Dosing Table

Semax is available in 0.1% and 1% concentrations. The 1% version is more economical but requires precise dosing — 1 drop delivers approximately 50 µg versus 5 µg for the 0.1% version.

What to Expect Realistically

Within the first week: Some users report noticeable effects from the first dose — increased verbal fluency, reduced mental friction, mild mood lift. These early effects may partly reflect novelty and expectation. Selank’s anxiolytic effect is often felt quickly.

Weeks 2–3: If there is a neurotrophin-mediated effect (BDNF/NGF upregulation is not instantaneous), more stable changes in focus and memory consolidation may emerge.

What this combination is not: It is not a replacement for sleep, adequate nutrition, or exercise. Neurotrophin effects are dose-dependent and context-dependent. In a cognitively depleted state it may help more than baseline. It will not produce dramatic stimulant-like alertness — that is not the mechanism.

Realistic ceiling: Both compounds have Russian clinical backing for pathological cognitive states (stroke recovery, anxiety disorders). The effect size in a healthy researcher with normal cognitive function is expected to be smaller. The evidence does not support claiming it makes a healthy brain dramatically smarter.

Summary

Semax and Selank are a rational pairing because they address different aspects of cognitive performance through non-overlapping mechanisms. The combination is low-risk in terms of interaction (no shared receptor systems), practical (both intranasal), and supported by meaningful human evidence at the individual compound level. The combination itself has not been studied in controlled trials.

For researchers interested in cognitive enhancement without the anxiety edge that stimulants produce, this is among the better-supported options in the peptide literature.

See also: Semax data page · Selank data page